Filing Details

Accession Number:
0001209191-20-046484
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-08-12 20:01:26
Reporting Period:
2020-08-10
Accepted Time:
2020-08-12 20:01:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1510487 Principia Biopharma Inc. PRNB Pharmaceutical Preparations (2834) 263487603
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1751719 M David Goldstein C/O Principia Biopharma Inc.
220 E. Grand Avenue
South San Francisco CA 94080
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-08-10 2,447 $3.00 34,186 No 4 M Direct
Common Stock Acquisiton 2020-08-10 3,553 $3.18 37,739 No 4 M Direct
Common Stock Disposition 2020-08-10 858 $86.11 36,881 No 4 S Direct
Common Stock Disposition 2020-08-10 700 $86.92 36,181 No 4 S Direct
Common Stock Disposition 2020-08-10 2,534 $88.40 33,647 No 4 S Direct
Common Stock Disposition 2020-08-10 700 $89.68 32,947 No 4 S Direct
Common Stock Disposition 2020-08-10 1,108 $90.99 31,839 No 4 S Direct
Common Stock Disposition 2020-08-10 100 $93.34 31,739 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2020-08-10 2,447 $0.00 2,447 $3.00
Common Stock Employee Stock Option (right to buy) Disposition 2020-08-10 3,553 $0.00 3,553 $3.18
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2023-10-23 No 4 M Direct
12,960 2024-06-26 No 4 M Direct
Footnotes
  1. Includes 771 shares acquired under the Employment Stock Purchase Plan on May 15, 2020.
  2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  3. Represents the weighted average sales price per share. The shares sold at prices ranging from $85.79 to $86.41 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  4. Represents the weighted average sales price per share. The shares sold at prices ranging from $88.12 to $88.78 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  5. Represents the weighted average sales price per share. The shares sold at prices ranging from $89.55 to $89.74 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  6. Represents the weighted average sales price per share. The shares sold at prices ranging from $90.85 to $91.49 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  7. The stock option is fully vested and immediately exercisable.